Tag: #semaglutide

FDA proposes excluding semaglutide, tirzepatide and liraglutide from 503B bulks list

FDA proposes removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, potentially limiting outsourcing facilities' ability to compound GLP‑1 drugs.

#fda, #glp1, #compounding, #semaglutide, #tirzepatide

23andMe study finds common gene variants modestly affect weight loss and nausea on GLP‑1 drugs

A Nature paper by 23andMe links common DNA variants to small differences in weight loss and nausea on GLP‑1 drugs; the company released a consumer report.

#genetics, #glp1, #23andme, #weightloss, #semaglutide